Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats

Digestive Diseases and Sciences

Volumn 42, Issue 5, 1997, Pages 920-926

  Barnes, Christopher J ^a   Hardman, Elaine ^a   Cameron, Ivan L ^a   Lee, Makau ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

aberrant crypt foci; aspirin; carcinogenesis; colon; indomethacin; nabumetone; prostaglandin E2; rat; sodium salicylate

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ACETYLSALICYLIC ACID; INDOMETACIN; NABUMETONE; PROSTAGLANDIN DERIVATIVE; SALICYLATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PREVENTION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CRYPT CELL; DRUG MECHANISM; HISTOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

1,2-DIMETHYLHYDRAZINE; 16,16-DIMETHYLPROSTAGLANDIN E2; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BUTANONES; CARCINOGENS; COLON; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DIMETHYLHYDRAZINES; INDOMETHACIN; MALE; RATS; RATS, SPRAGUE-DAWLEY; SODIUM SALICYLATE;

EID: 0030998262     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018812430512     Document Type: Article

References (33)

1. Thun MJ: Aspirin, NSAIDs, and digestive tract cancers. Cancer Metast Rev 13:269-277, 1994
2. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE: Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614, 1995
3. Reddy BS, Rao CV, Rivenson A, Kelloff G: Inhibitory effect of aspirin on azoxymethane-induced colon cardnogenesis in F344 rats. Carcinogenesis 14:1493-1497, 1993
4. Craven PA, DeRubertis FR: Effects of aspirin on 1,2-dimethylhydrazine-induced colonic Carcinogenesis. Carcinogenesis 13:541-546, 1992
5. Meade EA, Smith WL, DeWitt DL: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268:6610-6614, 1993
6. Marnett LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52:5575-5589, 1992
7. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL: Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 269:13207-13215, 1994
8. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188, 1984
9. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL: Differential inhibition of human prostaglandin endoperoxide synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271:927-934, 1994
10. Qiao L, Kozoni V, Tsioulias GJ, Koutsos MI, Hanif R, Shiff NSJ, Rigas B: Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1258:215-223, 1995
11. Pretlow TP: Aberrant crypt foci and K-ras mutations: Earliest recognized players or innocent bystanders in colon carcinogenesis. Gastroenterology 108:600-609, 1995
12. Yamashita N, Minamoto T, Ochiai A, Onda M, Esumi H: Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 108:434-440, 1995
13. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW: Molecular determinants of dysplasia in colorectal lesions. Cancer Res 54:5523-5526, 1994
14. Tudek B, Bird RP, Bruce WR: Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with foods. Cancer Res 49:1236-1240, 1989
15. Wargovich MJ, Chen C, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K, Kelloff GJ: Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 5:355-360, 1996
16. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, Stellato TA: Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res 51:1564-1567, 1991
17. Roncucci L, Medline A, Bruce WR: Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol Biomarkers Prev 1:57-60, 1991
18. Caderni G, Giannini A, Lancioni L, Luceri C, Biggeri A, Dolara P: Characterization of aberrant crypt foci in carcinogen-treated rats: Association with intestinal carcinogenesis. Br J Cancer 71:763-769, 1995
19. Carter JW, Lancaster HK, Hardman WE, Cameron IL: Distribution of intestine-associated-lymphoid-tissue, aberrant crypt foci and tumors in the large bowel of 1,2-dimethylhydrazine-treated mice. Cancer Res 54:4304-4307, 1994
20. Hardman WE, Cameron IL: Letter to the editor. Carcinogenesis 17:1539-1540, 1996
21. Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M: Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer 60:515-519, 1995
22. Lasko CM, Bird RP: Modulation of aberrant crypt foci by dietary fat and caloric restriction: The effects of delayed intervention. Cancer Epidemiol Biomarkers Prev 4:49-55, 1995
23. Lee M, Feldman M: Nonessential role of leukotrienes as mediators of acute gastric mucosal injury induced by aspirin in rats. Dig Dis Sci 37:1282-1287, 1992
24. Cameron IL, Ord VA, Hunter KE, Heitman DW: Colon carcinogenesis: Modulation of progression. In Colon Cancer Cells. MP Moyer, G Poste (eds). Orlando, Academic Press, 1990, pp 63-84
25. Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer Lett 37:147-151, 1987
26. SAS Institute: SAS Language and Procedures: usage. Cary, North Carolina, SAS Institute, 1989
27. Pence BC, Dunn DM, Zhao C, Landers M, Wargovich MJ: Chemopreventive effects of calcium but not aspirin supplementation in cholic acid-promoted carcinogenesis: Correlation with intermediate endpoints. Carcinogenesis 16:757-765, 1995
28. Pollard M, Luckert PH: Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 70:1103-1105, 1983
29. Kargman S, Charleson S, Cartwright M, Frank J, Riendeau D, Mancini J, Evans J, O'Neill O: Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey and human gastrointestinal tracts. Gastroenterology 111:445-454, 1996
30. Abramson S, Korchak H, Ludewig R, Edelson H, Haines K, Levin RI, Herman R, Rider L, Kimmel S, Weissman G: Modes of action of aspirin-like drugs. Proc Natl Acad Sci USA 82:7227-7231, 1985
31. Abramson SB, Weissman G: The mechanisms of action of nonstoroidal antiinflammatory drugs. Arthritis Rheum 32:1-9, 1989
32. Kopp E, Ghosh S: Inhibition of NF-kB by sodium salicylate and aspirin. Science 265:956-959, 1994
33. Giardiello FM: Sulindac and polyp regression. Cancer Metast Rev 13:279-283, 1994